- Home
- FIP vs ORKA Comparison
FIP vs ORKA Comparison
Compare FIP & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIP
- ORKA
- Stock Information
- Founded
- FIP 2021
- ORKA 2004
- Country
- FIP United States
- ORKA United States
- Employees
- FIP N/A
- ORKA N/A
- Industry
- FIP Consumer Electronics/Appliances
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FIP Industrials
- ORKA Health Care
- Exchange
- FIP Nasdaq
- ORKA Nasdaq
- Market Cap
- FIP 715.0M
- ORKA 354.2M
- IPO Year
- FIP N/A
- ORKA N/A
- Fundamental
- Price
- FIP $6.58
- ORKA $12.60
- Analyst Decision
- FIP Buy
- ORKA Strong Buy
- Analyst Count
- FIP 1
- ORKA 8
- Target Price
- FIP $12.00
- ORKA $39.71
- AVG Volume (30 Days)
- FIP 1.2M
- ORKA 341.3K
- Earning Date
- FIP 07-31-2025
- ORKA 08-15-2025
- Dividend Yield
- FIP 1.82%
- ORKA N/A
- EPS Growth
- FIP N/A
- ORKA N/A
- EPS
- FIP N/A
- ORKA N/A
- Revenue
- FIP $345,123,000.00
- ORKA N/A
- Revenue This Year
- FIP $65.61
- ORKA N/A
- Revenue Next Year
- FIP $30.50
- ORKA N/A
- P/E Ratio
- FIP N/A
- ORKA N/A
- Revenue Growth
- FIP 5.70
- ORKA N/A
- 52 Week Low
- FIP $3.10
- ORKA $5.49
- 52 Week High
- FIP $10.46
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- FIP 59.51
- ORKA N/A
- Support Level
- FIP $6.04
- ORKA N/A
- Resistance Level
- FIP $6.45
- ORKA N/A
- Average True Range (ATR)
- FIP 0.27
- ORKA 0.00
- MACD
- FIP -0.05
- ORKA 0.00
- Stochastic Oscillator
- FIP 51.25
- ORKA 0.00
About FIP FTAI Infrastructure Inc.
FTAI Infrastructure Inc is engaged in five segments; Railroad segment includes five freight railroads and one switching company that provide rail service to certain manufacturing and production facilities, the Jefferson Terminal segment consists of a multi-modal crude oil and refined products terminal and other related assets. Repauno segment consists of a 1,630-acre deep-water port located along the Delaware River with an underground storage cavern, a new multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities. Power and Gas segment is comprised of an equity method investment in Long Ridge, and Sustainability and Energy Transition segment is comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.